Pfizer Inc. PFE SPXR3KPHARMA
Company Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Why Investors Should Care
Operating margin of 27.9% supports profitability.
Offers a dividend yield of 6.22%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $62.58B (-1.6% YoY); net profit $7.77B.
- Trailing 12 Months Year-on-year growth — revenue +2.6%, earnings -3.2%.
- 5-Year Trend Long-term compounding — revenue CAGR 1.4%, profit CAGR -0.3%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 1.44% |
| 1 Year: | 2.60% |
Compounded Profit Growth
| 5 Years: | -0.26% |
| 1 Year: | -3.24% |
Stock Price Performance
| 1 Year: | +29.39% |
| 6 Months: | +17.97% |
| 3 Months: | +23.96% |
| 1 Month: | +7.95% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)72.19 · Overbought
P/E of 40.03 is above the sector median of 25.61 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Attractive dividend yield of 6.22%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -0.3% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PFE Pfizer Inc. SPXR3KPHARMA | 30.42 | 40.03 | $173.38B | 6.22% | - | 5.01% | 1.44% | -0.26% |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2013 | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Apr 2016 | Jul 2016 | Oct 2016 | Apr 2017 | Jul 2017 | Oct 2017 | Apr 2018 | Jul 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Apr 2021 | Jul 2021 | Oct 2021 | Apr 2022 | Jul 2022 | Oct 2022 | Apr 2023 | Jul 2023 | Oct 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 12.90B | 13.17B | 12.91B | 13.47B | 13.30B | 13.12B | 13.26B | 12.68B | 10.08B | 9.86B | 10.28B | 14.52B | 18.90B | 24.04B | 25.66B | 27.74B | 22.64B | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | 14.10B | 2.59B | 2.33B | 2.91B | 2.67B | 2.38B | 2.63B | 2.13B | 3.04B | 2.05B | 1.35B | 3.12B | 3.07B | 2.84B | 3.56B | 3.87B | 4.11B | 3.88B | 5.05B | 7.68B | 3.35B | 3.49B | 1.47B | 4.88B | 5.56B | 8.15B | 7.86B | 9.91B | 8.61B | 5.54B | 2.33B | -2.38B | 3.12B | 41.00M | 4.46B | 2.97B | 2.91B | 3.54B | 2.69B | -248.00M |
| Diluted EPS | 1.98 | 0.39 | 0.36 | 0.45 | 0.42 | 0.38 | 0.42 | 0.34 | 0.49 | 0.33 | 0.22 | 0.51 | 0.51 | 0.47 | 0.59 | 0.65 | 0.69 | 0.68 | 0.89 | 1.36 | 0.60 | 0.62 | 0.26 | 0.86 | 0.98 | 1.42 | 1.37 | 1.73 | 1.51 | 0.97 | 0.41 | -0.42 | 0.55 | 0.01 | 0.78 | 0.52 | 0.51 | 0.62 | 0.47 | -0.04 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.42B | 48.30B | 49.27B | 65.17B | 61.03B | 54.66B | 51.58B | 49.60B | 48.85B | 52.82B | 52.55B | 40.83B | 40.91B | 41.65B | 73.64B | 91.79B | 50.91B | 63.63B | 62.58B |
| Net Income | 8.14B | 8.10B | 8.63B | 8.26B | 10.01B | 14.57B | 22.00B | 9.13B | 6.96B | 7.21B | 21.31B | 11.15B | 16.03B | 9.16B | 21.98B | 31.37B | 2.12B | 8.03B | 7.77B |
| Diluted EPS | 1.17 | 1.20 | 1.23 | 1.02 | 1.27 | 1.94 | 3.19 | 1.42 | 1.11 | 1.17 | 3.52 | 1.87 | 2.82 | 1.63 | 3.85 | 5.47 | 0.37 | 1.41 | 1.36 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Sep 2009 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 111.15B | - | 212.95B | 195.01B | 188.00B | 185.80B | 172.10B | 167.57B | 167.38B | 171.62B | 171.80B | 159.42B | 167.59B | 154.23B | 181.48B | 197.21B | 226.50B | 213.40B | 208.16B |
| Total Equity | 71.43B | 65.12B | 57.56B | - | 90.01B | 87.81B | 82.19B | 81.26B | 76.31B | 71.30B | 64.72B | 59.54B | 71.31B | 63.41B | 63.14B | 63.24B | 77.20B | 95.66B | 89.01B | 88.20B | 86.48B |
| Cash & Equivalents | 1.83B | 3.41B | 2.12B | 4.23B | 1.98B | 1.74B | 3.18B | 10.08B | 2.18B | 3.34B | 3.64B | 2.60B | 1.34B | 1.14B | 1.12B | 1.79B | 1.94B | 416.00M | 2.85B | 1.04B | 1.14B |
| Long Term Debt | - | - | 7.96B | - | 43.19B | 38.41B | 34.93B | 31.04B | 30.46B | 31.54B | 28.74B | 31.40B | 33.54B | 32.91B | 35.95B | 37.13B | 36.20B | 32.88B | 61.54B | 57.41B | 61.64B |
| Total Liabilities | - | - | 53.41B | - | 122.50B | 106.75B | 105.38B | 104.12B | 95.48B | 95.94B | 102.38B | 111.78B | 100.14B | 95.66B | 104.15B | 90.76B | 104.01B | 101.29B | 137.21B | 124.90B | 121.39B |
| Current Liabilities | - | - | 27.01B | - | 37.23B | 28.64B | 28.91B | 29.19B | 23.37B | 21.59B | 29.40B | 31.11B | 30.43B | 31.86B | 37.30B | 25.92B | 42.67B | 42.14B | 47.79B | 42.99B | 36.98B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 13.35B | 18.24B | 16.59B | 11.45B | 20.24B | 16.75B | 17.68B | 17.08B | 14.69B | 16.19B | 16.80B | 15.83B | 12.59B | 14.40B | 32.58B | 29.27B | 8.70B | 12.74B | 11.70B |
| Investing Cash Flow | 795.00M | -12.84B | -31.27B | -492.00M | 1.84B | 6.15B | -10.54B | -5.65B | -2.98B | -7.79B | -4.74B | 4.53B | -3.94B | -4.27B | -22.55B | -15.78B | -32.28B | 2.65B | -1.35B |
| Financing Cash Flow | -12.61B | -6.56B | 14.48B | -11.17B | -20.61B | -16.00B | -14.97B | -10.19B | -10.41B | -9.23B | -13.35B | -20.44B | -8.48B | -9.65B | -9.82B | -14.83B | 26.07B | -17.14B | -10.30B |
| Capital Expenditure | -1.88B | -1.70B | -1.21B | -1.51B | -1.66B | -1.33B | -1.21B | -1.20B | -1.40B | -1.82B | -1.96B | -1.98B | -2.05B | -2.23B | -2.71B | -3.24B | -3.91B | -2.91B | -2.63B |
| Free Cash Flow | 11.47B | 16.54B | 15.38B | 9.94B | 18.58B | 15.42B | 16.48B | 15.88B | 13.29B | 14.37B | 14.85B | 13.84B | 10.54B | 12.18B | 29.87B | 26.03B | 4.79B | 9.84B | 9.07B |
| Share Buybacks | 9.99B | 500.00M | 0 | 1.00B | 9.00B | 8.23B | 16.29B | 5.00B | 6.16B | 5.00B | 5.00B | 12.20B | 8.87B | 0 | 0 | 2.00B | 0 | 0 | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | 16.8% | 16.8% | 17.5% | 12.7% | 16.4% | 26.7% | 42.7% | 18.4% | 14.2% | 13.7% | 40.6% | 27.3% | 39.2% | 22.0% | 29.8% | 34.2% | 4.2% | 12.6% | 12.4% |
| ROE % | 12.5% | 14.1% | 9.6% | 9.4% | 12.2% | 17.9% | 28.8% | 12.8% | 10.8% | 12.1% | 29.9% | 17.6% | 25.4% | 14.5% | 28.5% | 32.8% | 2.4% | 9.1% | 9.0% |
| ROCE % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 9.29% | 529.67M | $14.98B |
| 2 | Vanguard Capital Management LLC | 6.53% | 372.15M | $10.52B |
| 3 | State Street Corporation | 5.39% | 307.09M | $8.68B |
| 4 | Geode Capital Management, LLC | 2.37% | 135.28M | $3.83B |
| 5 | Vanguard Portfolio Management LLC | 2.09% | 119.24M | $3.37B |
| 6 | Fisher Asset Management, LLC | 1.91% | 109.07M | $3.08B |
| 7 | Morgan Stanley | 1.69% | 96.35M | $2.72B |
| 8 | NORGES BANK | 1.08% | 61.51M | $1.74B |
| 9 | Northern Trust Corporation | 1.04% | 59.08M | $1.67B |
| 10 | Bank Of New York Mellon Corporation | 1.02% | 57.88M | $1.64B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PFE
How To Boost The Dividend Yield On This Drugmaking Behemoth - Investor's Business Daily
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNQ0NpWENzSnJwcUxsVVBFMlJBa2wwb0FxOXFXZWtXazZFOEdYajVLTEdCdG0xaV9IMG1aVkp0V19fRVVWMFBLY3dLRDFKdTZqZmlhQ0VSNzBVY3RGZFc3bDdkanlHd3JqbnpDR1FPdWtMZHBISkFvVWFqU3VMZkg4cFozZ0hMVTZHQmxtUE…
Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxPcEJfdzlMUl9wcnFZbUpPTWJ6UWRwcG1QWExtV21vS2FuZ1YtUlUtLUQ0VUxqWDZKSlpKYi1FSUVPV1o4RVBramZSaGI0RDZScDd4RnRZWVREX1p5OUJxR0hNbXdnN3JSdXl1a1czZl9vMkc4cUdGUy1xck9RSk1OREZlNGxCQzBPTFB1Qz…
Moderna Tumbles 25% After Apparent Early Leak of Melanoma Vaccine Data; BioNTech Dips, Pfizer Edges Higher - 24/7 Wall St.
<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxPOFltVUdHTFd2S1p0LVpXalpmLVhBQVFxdGRkeERIdHBlNXRNNzYtYTVUNzBzcHZFdGtDVXM4TjBIWktaLUkxaHhwNElsS2tIWFVxUGpLNTNITTZnZVhQM2t3R0Q4VF95aFA0bGkwbjFBQldrVnpiV3pyeWR1aXdjeFpCeFlYTGlRa1NJWU…
Should You Buy Pfizer Stock For Its Cash? - Trefis
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOZU9GLWFBMXM2dndSWDFPaWI2YUx2aV9zZnMyWWotVUZON1JHbTJBQjZaVTk5dUpxMDBySlV2VHQ3eDFDRE9VeTYzU2ZqMFhqV2J2c3MwUnM3Nm0yZThCbEdsdnNvMXFrSGpkTDBvaHBjV1VxcUhpcXN5WVBidEQ0N2xTaWVnbFduSmFGaT…
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPbHdlNnFXOWZIVndoeEt3WTAyU0hTdDB1MnFuWV9JSURsTEJmc0lpQzBGWXY5a3h4dDVDZ2JBb3ZYV2R1c1ZYRThsdGlWTlUydHl4MEktX3J3cXlFOFc2OGluZzFBc0dkWVZsUmFMcWtlTEw0R1RVR3hyN1lfTUgyQXVvWVJ4WE14QV92Mz…
Pfizer's Stock Is Finally Showing Signs of Life. Could This Be the Start of a Much Bigger Rally? - The Motley Fool
<a href="https://news.google.com/rss/articles/CBMi0wFBVV95cUxPLUcwQ2FRR1hVM0JPcjRDbFRPenZ1b3dSNU1KbVgzYktHaEZnYmxacHpiTEFub3BxTGdxdUdBSUpzVnVGaXRDN0tWQk9KeU1SaWRFR05rRWlhZF9WWi1kMUEyWmlCdm9pc1FoZXFMbF85cUYyaXFBQ2JWVHBmMThkdFFMa25wZGNiODYxem…
PFE — Frequently Asked Questions
What is the current share price of Pfizer Inc. (PFE)?
As of 2026-10-22 16:30 PDT, Pfizer Inc. (PFE) trades at $30.42 on NYSE. Its 52-week range is $22.05 to $30.42.
What is the market capitalisation of PFE?
Pfizer Inc. (PFE) has a market capitalisation of $173.38B on NYSE.
What is the P/E ratio of PFE?
PFE trades at a trailing price-to-earnings (P/E) ratio of 40.03. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is 1.85.
Does PFE pay a dividend?
Pfizer Inc. (PFE) currently offers a dividend yield of 6.22%.
What is the return on equity (ROE) of PFE?
PFE has a return on equity (ROE) of 5.01%.
Is PFE a good stock to buy?
This page provides a data-driven analysis of Pfizer Inc. (PFE), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.